FIELD: medicine.
SUBSTANCE: presented group of inventions refers to medicine. What is presented is application of IL-1β binding antigen for producing a drug preparation for treating juvenile rheumatoid arthritis in a patient, containing at least one antigen-binding centre which involves a first domain having an amino acid sequence specified in SEQ ID NO:1, and a second domain having an amino acid sequence specified in SEQ ID NO:2. What is presented is a pharmaceutical composition containing said antibody in a combination with pharmaceutically acceptable excipients, solvents or carriers introduced parenterally.
EFFECT: presented group of inventions provides new application of IL-1β binding antibody for treating juvenile rheumatoid arthritis, particularly systemic idiopathtic juvenile rheumatoid arthritis in mammals, particularly in a human.
10 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
| ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
| FORMULATIONS CONTAINING ANTIBODIES | 2009 |
|
RU2745601C2 |
| IL-18-BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASES | 2016 |
|
RU2755691C2 |
| IL-18 BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN TREATING INFLAMMATORY DISEASES | 2016 |
|
RU2810206C1 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
